Navigation Links
YM BIOSCIENCES REPORTS 2007 YEAR END OPERATIONAL AND FINANCIAL RESULTS
Date:9/23/2007

gns was designed and,

subsequent to the fiscal year-end, has been submitted.

Tesmilifene:

In January 2007, the Data Safety Monitoring Board (DSMB) overseeing the 'DEC' Phase III pivotal trial of tesmilifene in combination with epirubicin and cyclophosphamide for the treatment of rapidly progressing metastatic breast cancer completed the third planned interim analysis. Evaluating data that included 351 patient events, the DSMB advised the Company that, although there were no safety concerns and that the trial was well conducted, it was highly unlikely to meet its primary efficacy endpoint. YM terminated the trial and, with the exception of one further follow-up for confirmation expected in calendar Q4 2007 and the ongoing collaborative trial with Sanofi-Aventis in metastatic breast cancer for which pharmacokinetic data should be available by calendar year-end 2007, we intend to undertake no further clinical development.

Financial Results (CDN dollars)

Total revenue for the fiscal year ended June 30, 2007 was $7.6 million compared to $2.5 million for the fiscal year ended June 30, 2006. Total revenue for the fourth quarter ended June 30, 2007 was $1.9 million compared to $1.1 million for the same quarter last year.

Revenue from out-licensing increased by $3.3 million in fiscal 2007 compared to fiscal 2006 as a result of two out-licensing agreements entered into during the year. The most significant agreement, signed with Daiichi Pharmaceutical Co., Ltd. in July 2006, licensed the commercial rights for nimotuzumab for Japan and included a non-refundable up-front payment from Daiichi to the Company of $16.2 million. This initial license fee has been recorded as deferred revenue and is being recognized over a period of four years.

Interest income for fiscal 2007 increased by $1.8 million compared to fiscal 2006, attributable to the significant increase in cash which resulted from the US$40 million prospectus-based financing i
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Senior supply chain ... professional associations, addressed the challenges of “Reducing Cost, Lead ... Industries” through strategic sourcing. Describing the partnership of the ... Supply Chain Management Institute ( SCMI) of the ... June 24 at the Kroc Institute of Peace and ...
(Date:7/10/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/s3bqj2/photonic ) has ... Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... traces its roots in the latter half of ... went unexplored and unfulfilled for several decades owing ...
(Date:7/10/2014)... PNAS (Proceedings of the National Academy of Sciences) ... deprivation have a significant effect on our metabolism. The ... time of day to test for diseases such as ... , Researchers from the University of Surrey and The ... sleep deprivation, body clock disruption and metabolism, and discovered ...
(Date:7/10/2014)... Since the 1960s, theatergoers have shelled out for ... to enhance their viewing experience. These basic devices, ... artificial three-dimensional reality, may soon be rendered obsolete ... by Tel Aviv University researchers. , TAU doctoral ... have developed highly efficient holography based on nanoantennas ...
Breaking Biology Technology:Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Time of day crucial to accurately test for diseases, new research finds 2Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3
... Pacira Pharmaceuticals, Inc., an,acute care specialty pharmaceutical company, today ... addition of a key senior,executive to the company,s management ... a seasoned biopharmaceutical executive with more than,30 years of ... Pacira as the founder and past Chairman and CEO ...
... WOODCLIFF LAKE, N.J., July 9 Par,Pharmaceutical Companies, Inc. ... shipment of 12.5mg and 25mg meclizine HCl tablets immediately. ... of the AB-rated,generic product., Par marketed meclizine prior ... in February 2008. Par has since qualified a new ...
... 9 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. (TSX:,LOR, ... biopharmaceutical company,specializing in the research and development ... of cancer, today announced progress made in,the ... two,research studies on the Virulizin(R) mode of ...
Cached Biology Technology:Pacira Pharmaceuticals, Inc. Adds Board Member and Key Senior Management 2Par Pharmaceutical to Launch meclizine HCL Tablets 2Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 2Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 3Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 4Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 5Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 6
(Date:7/11/2014)... Evidence exists that cannabinoid receptor type 1 ... Ca2+ influx, and reduce neurotransmitter release. However, ... 1 can increase extracellular Ca2+ influx and ... his team, Tongji Hospital Affiliated to Tongji ... Technology, China used whole cell voltage-clamp and ...
(Date:7/10/2014)... COLORADO SPRINGS, Colo. , June 27, 2014 ... announces that the National Institute of Standards and ... appointed 10 of its academic research and forensic ... Board (FSSB).  The Board is an element of ... These AAFS members are among the first appointments ...
(Date:7/10/2014)... 2, 2014 It is a great honor ... appointment of the world-renowned Thoracic and Cardiovascular surgeon, Mark ... Dr. Ginsburg, with over 34 years of experience, ... and Good Samaritan Regional Medical Center. Dr. Ginsburg has ... 1980,s and is considered an expert in the implantation ...
Breaking Biology News(10 mins):Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
... Ph.D., School of Biosciences, University of Birmingham, has ... his seminal work on the structural biology and ... cell walls in bacteria. Natalie Strynadka, University of ... "his spectacular abilities in structural biology clearly paved ...
... than three quarters of the volume of material destined for geological ... is to encapsulate ILW in specially formulated cement. The waste is ... disposal deep underground. Two studies, published in the latest issues ... Journal of Glass Science and Technology A show that turning ...
... Sea, a salt sea without an outlet, lies over ... salt content because it increases their buoyancy. "For ... that provides a diachronic view of its climate past," ... Geology, Mineralogy and Paleontology at the University of Bonn. ...
Cached Biology News:The American Society for Microbiology honors Andrew Lovering 2Glass offers improved means of storing UK's nuclear waste 2Drastic desertification 2Drastic desertification 3
D.R. Harper (1993) • Includes: essential information on taxonomy, culture and safe handling of viruses, immunology, monoclonal antibodies, antivirals and vaccines....
...
Performance, mycoplasma, virus, and endotoxin tested. Collected from calves 14 days old or less...
...
Biology Products: